354 related articles for article (PubMed ID: 16165718)
1. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease.
Erichsen K; Ulvik RJ; Nysaeter G; Johansen J; Ostborg J; Berstad A; Berge RK; Hausken T
Scand J Gastroenterol; 2005 Sep; 40(9):1058-65. PubMed ID: 16165718
[TBL] [Abstract][Full Text] [Related]
2. Effects of ferrous sulphate and non-ionic iron-polymaltose complex on markers of oxidative tissue damage in patients with inflammatory bowel disease.
Erichsen K; Ulvik RJ; Grimstad T; Berstad A; Berge RK; Hausken T
Aliment Pharmacol Ther; 2005 Nov; 22(9):831-8. PubMed ID: 16225492
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers.
Ricanek P; Brackmann S; Perminow G; Lyckander LG; Sponheim J; Holme O; Høie O; Rydning A; Vatn MH;
Scand J Gastroenterol; 2011 Sep; 46(9):1081-91. PubMed ID: 21619483
[TBL] [Abstract][Full Text] [Related]
5. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease.
Scarpa M; D'Incà R; Basso D; Ruffolo C; Polese L; Bertin E; Luise A; Frego M; Plebani M; Sturniolo GC; D'Amico DF; Angriman I
Dis Colon Rectum; 2007 Jun; 50(6):861-9. PubMed ID: 17473939
[TBL] [Abstract][Full Text] [Related]
6. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
[TBL] [Abstract][Full Text] [Related]
7. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial.
Kulnigg S; Stoinov S; Simanenkov V; Dudar LV; Karnafel W; Garcia LC; Sambuelli AM; D'Haens G; Gasche C
Am J Gastroenterol; 2008 May; 103(5):1182-92. PubMed ID: 18371137
[TBL] [Abstract][Full Text] [Related]
8. Effect of intravenous iron sucrose on oxidative stress in peritoneal dialysis patients.
Saglam F; Cavdar C; Uysal S; Cavdar Z; Camsari T
Ren Fail; 2007; 29(7):849-54. PubMed ID: 17994454
[TBL] [Abstract][Full Text] [Related]
9. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
[TBL] [Abstract][Full Text] [Related]
10. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study.
Schröder O; Mickisch O; Seidler U; de Weerth A; Dignass AU; Herfarth H; Reinshagen M; Schreiber S; Junge U; Schrott M; Stein J
Am J Gastroenterol; 2005 Nov; 100(11):2503-9. PubMed ID: 16279906
[TBL] [Abstract][Full Text] [Related]
11. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of oral and intravenous iron therapy in haemodialysis patients.
Jenq CC; Tian YC; Wu HH; Hsu PY; Huang JY; Chen YC; Fang JT; Yang CW
Int J Clin Pract; 2008 Mar; 62(3):416-22. PubMed ID: 17511797
[TBL] [Abstract][Full Text] [Related]
13. A 12-week randomised study comparing intravenous iron sucrose versus oral ferrous sulphate for treatment of postpartum anemia.
Westad S; Backe B; Salvesen KA; Nakling J; Økland I; Borthen I; Rognerud Jensen OH; Kolås T; Løkvik B; Smedvig E
Acta Obstet Gynecol Scand; 2008; 87(9):916-23. PubMed ID: 18720044
[TBL] [Abstract][Full Text] [Related]
14. Faecal calprotectin in the assessment of Crohn's disease activity.
Gaya DR; Lyon TD; Duncan A; Neilly JB; Han S; Howell J; Liddell C; Stanley AJ; Morris AJ; Mackenzie JF
QJM; 2005 Jun; 98(6):435-41. PubMed ID: 15879440
[TBL] [Abstract][Full Text] [Related]
15. Oxidative stress in hemodialysis patients receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative stress.
Swarnalatha G; Ram R; Neela P; Naidu MU; Dakshina Murty KV
Saudi J Kidney Dis Transpl; 2010 Sep; 21(5):852-8. PubMed ID: 20814119
[TBL] [Abstract][Full Text] [Related]
16. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: A randomized, controlled, evaluator-blind, multicentre study.
Lindgren S; Wikman O; Befrits R; Blom H; Eriksson A; Grännö C; Ung KA; Hjortswang H; Lindgren A; Unge P
Scand J Gastroenterol; 2009; 44(7):838-45. PubMed ID: 19330567
[TBL] [Abstract][Full Text] [Related]
17. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease.
Winterkamp S; Weidenhiller M; Otte P; Stolper J; Schwab D; Hahn EG; Raithel M
Am J Gastroenterol; 2002 Dec; 97(12):3071-7. PubMed ID: 12492192
[TBL] [Abstract][Full Text] [Related]
18. Decreased treatment failure rates following duodenal release ferrous glycine sulfate in iron deficiency anemia associated with autoimmune gastritis and Helicobacter pylori gastritis.
Hershko C; Ianculovich M; Souroujon M
Acta Haematol; 2007; 118(1):19-26. PubMed ID: 17426393
[TBL] [Abstract][Full Text] [Related]
19. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease.
Folwaczny C; Wiebecke B; Loeschke K
Am J Gastroenterol; 1999 Jun; 94(6):1551-5. PubMed ID: 10364024
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trial.
de Silva AD; Tsironi E; Feakins RM; Rampton DS
Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1097-105. PubMed ID: 16305723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]